Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Arcutis Biotherapeutics, Inc.
13G
ARQT · 03969K108
|
5.3% |
8/14/2026
Event 6/30/2026
|
|||
| Polar Capital Holdings Plc | 5.3% | ||||
| Polar Capital LLP | 5.3% | ||||
|
Verastem, Inc.
13G/A
VSTM · 92337C203
|
4.8% |
7/8/2026
Event 3/31/2026
|
|||
| Polar Capital Holdings Plc | 4.8% | ||||
| Polar Capital LLP | 4.8% | ||||
| Polar Capital Funds PLC - Biotechnology Fund | 4.8% | ||||
|
Enliven Therapeutics, Inc.
13G/A
ELVN · 29337E102
|
8.5% |
6/22/2026
Event 3/31/2026
|
|||
| Polar Capital Holdings Plc | 8.5% | ||||
| Polar Capital LLP | 8.5% | ||||
| Polar Capital Funds PLC - Biotechnology Fund | 8.5% | ||||
|
Hagerty, Inc.
13G/A
HGTY · 405166109
|
5.9% |
9/4/2025
Event 6/30/2025
|
|||
| Polar Capital Holdings Plc | 5.9% | ||||
| Polar Capital LLP | 5.9% | ||||
| Polar Capital Funds PLC - Biotechnology Fund | 5.9% | ||||
|
NeuroPace Inc
13G
NPCE · 641288105
|
9.1% |
5/15/2025
Event 3/31/2025
|
|||
| Polar Capital Holdings Plc | 9.1% | ||||
| Polar Capital LLP | 9.1% | ||||
|
Vtex
13G/A
VTEX · G9470A102
|
2.8% |
2/14/2025
Event 12/31/2024
|
|||
| Polar Capital Holdings Plc | 2.8% | ||||
| Polar Capital LLP | 2.8% | ||||
| Polar Capital Funds PLC - Biotechnology Fund | 2.8% | ||||